committee will also hear and discuss post approval study reports for two recently approved neurological device premarket approval applications: The VNS Therapy™ System, sponsored by Cyberonics, Inc., for treatment-resistant chronic or recurrent depression; and the Dural Sealant System, sponsored by Confluent Surgical, Inc., for use as an adjunct to sutured dural repair during cranial surgery to provide watertight closure.

FDA intends to make background material available to the public no later than 1 business day before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting. Background material is available at http://www.fda.gov/ohrms/dockets/ac/acmenu.htm, click on the year 2007 and scroll down to the appropriate advisory committee link.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app.2) and 21 CFR part 14, relating to the advisory committees.

Dated: December 18, 2006.

Randall W. Lutter,
Associate Commissioner for Policy and Planning.

[FR Doc. E6–21995 Filed 12–22–06; 8:45 am]
BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (HHS) notifies Federal agencies of the laboratories currently certified to meet the standards of Subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the Federal Register on April 11, 1988 (53 FR 11970), and subsequently revised in the Federal Register on June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on April 13, 2004 (69 FR 19644). A notice listing all currently certified laboratories is published in the Federal Register during the first week of each month. If any laboratory’s certification is suspended or revoked, the laboratory will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any laboratory has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at http://workplace.samhsa.gov and http://www.druifreeworkplace.gov.

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, SAMHSA/CSAP, Room 2–1035, 1 Choke Cherry Road, Rockville, Maryland 20857; 240–276–2600 (voice), 240–276–2610 (fax).

SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were developed in accordance with Executive Order 12564 and section 503 of Public Law 100–71. Subpart C of the Mandatory Guidelines, “Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies,” sets strict standards that laboratories must meet in order to conduct drug and specimen validity tests on urine specimens for Federal agencies. To become certified, an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A laboratory must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Mandatory Guidelines dated April 13, 2004 (69 FR 19644), the following laboratories meet the minimum standards to conduct drug and specimen validity tests on urine specimens: ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227. 414–328–7840/800–877–7016. (Formerly: Bayshore Clinical Laboratory).


Baptist Medical Center—Toxicology Laboratory, 9601 I–630, Exit 7, Little Rock, AR 72205–7299. 501–202–2783. (Formerly: Forensic Toxicology Laboratory Baptist Medical Center).


Diagnostic Services, Inc., dba DSI, 12700 Westlinks Drive, Fort Myers, FL 33913. 239–561–8200/800–735–5416.

Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602. 229–671–2281.

DrugScan, Inc., P.O. Box 2969, 1119 Mearns Road, Warminster, PA 18974. 215–674–9310.


General Medical Laboratories, 36 South Brooks St., Madison, WI 53715. 608–267–6225.

Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 70053. 504–361–8999/800–433–3823. (Formerly: Laboratory Specialists, Inc.).


Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040. 713–856–8288/800–800–2387.

Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869. 908–526–2400/800–437–4986. (Formerly: Roche Biomedical Laboratories, Inc.).


Laboratory Corporation of America Holdings, 10788 Rosselle St., San
Physician's Reference Laboratory, 7800
National Toxicology Laboratories, Inc.,
Minneapolis Veterans Affairs Medical
Laboratory Corporation of America
Marshfield Laboratories, Forensic
Laboratory Corporation of America
Toxicology Laboratory.

University of Texas Medical Branch,
77504. 888
66210. 913

Laboratories, 110 West Cliff Dr.,
Bakersfield, CA 93301. 661

Laboratory Services, a Division of
LabOne, Inc.);

Laboratory of
Seattle, Inc.);

Pathology, LLC; Laboratory of
Seattle, Inc.);

Occupational Testing Services, Inc.;

Testing Center, St. Lawrence Campus,
Las Vegas, NV 89119–5412. 702–733–
7866/800–433–2750. (Formerly:
Associated Pathologists Laboratories,
Inc.).

Quest Diagnostics Incorporated, 400
Egypt Road, Norristown, PA 19403.
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline Bio-
Science Laboratories).

Quest Diagnostics Incorporated, 506 E.
State Pkwy., Schaumburg, IL 60173.
(Formerly: SmithKline Beecham
Clinical Laboratories; International
Toxicology Laboratories).

Quest Diagnostics Incorporated, 7600
Tyrone Ave., Van Nuys, CA 91405.
(Formerly: SmithKline Beecham
Clinical Laboratories).

Quest Diagnostics Incorporated, 2282
South Presidents Drive, Suite C, West
Valley City, UT 84120. 801–606–
6301/800–322–3361. (Formerly:
Northwest Toxicology, a LabOne
Company). (db) SmithKline Beecham
Northwest Toxicology; NWT Drug
Testing, NorthWest Toxicology, Inc.;
Northwest Drug Testing, a division of
NWT Inc.).

S.E.D. Medical Laboratories, 5601 Office
Blvd., Albuquerque, NM 87109. 505–

South Bend Medical Foundation, Inc.,
530 N. Lafayette Blvd., South Bend,
IN 46601. 574–234–4176 x276.

Southwest Laboratories, 4645 E. Cotton
Center Boulevard, Suite 177, Phoenix,
AZ 85040. 602–438–8507/800–279–
0027.

Sparrow Health System, Toxicology
Testing Center, St. Lawrence Campus,
1210 W. Saginaw, Lansing, MI 48915.
517–364–7400. (Formerly: St.
Lawrence Hospital & Healthcare
System).

St. Anthony Hospital Toxicology
Laboratory, 1000 N. Lee St.,
Oklahoma City, OK 73101. 405–272–
7052.

Toxicology & Drug Monitoring
Laboratory, University of Missouri
Hospital & Clinics, 301 Business Loop
70 West, Suite 208, Columbia, MO
65203. 573–882–1273.

Toxicology Testing Service, Inc., 5426
N.W. 79th Ave., Miami, FL 33166.
305–593–2260.

US Army Forensic Toxicology Drug
Testing Laboratory, 2490 Wilson St.,
Fort George G. Meade, MD 20755–
5235. 301–677–7085.

* The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with the
HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory (Federal
Register, July 16, 1996) as meeting the
minimum standards of the Mandatory
Guidelines published in the Federal
Register on April 13, 2004 (69 FR
19644). After receiving DOT
certification, the laboratory will be
included in the monthly list of HHS-
certified laboratories and participate in
the NLCP certification maintenance
program.

Elaine Parry,
Acting Director, Office Program Services,
SAMHSA.

[F.R. Doc. E6–22049 Filed 12–22–06; 8:45 am]

BILLING CODE 4162–20–P

DEPARTMENT OF HOMELAND SECURITY

Bureau of Customs and Border Protection

Automated Commercial Environment
(ACE); National Customs Automation
Program Test of Automated Truck
Manifest for Truck Carrier Accounts;
Deployment Schedule

AGENCY: Customs and Border Protection; Department of Homeland Security.

ACTION: General notice.